Metal-assisted red light-induced DNA cleavage by ternary L-methionine copper(II) complexes of planar heterocyclic bases

Ternary copper(II) complexes [Cu(L-met)B(Solv)](ClO4) (1-4), where B is a N,N-donor heterocyclic base like 2,2-bipyridine (bpy, 1), 1,10-phenanthroline (phen, 2), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq, 3) and dipyrido[3,2-a:2',3'-c]phenazene (dppz, 4), are prepared and their DNA binding and photoinduced DNA cleavage activity studied (L-Hmet=L-methionine). Complex 2, structurally characterized by X-ray crystallography, shows a square pyramidal (4+1) coordination geometry in which the N,O-donor L-methionine and N,N-donor heterocyclic base bind at the basal plane and a solvent molecule is coordinated at the axial site. The complexes display a d-d band at ~600 nm in DMF and exhibit a cyclic voltammetric response due to the Cu(II)/Cu(I) couple near -0.1 V in DMF-Tris-HCl buffer. The complexes display significant binding propensity to the calf thymus DNA in the order: 4 (dppz) > 3 (dpq) > 2 (phen) » 1 (bpy). Control cleavage experiments using pUC19 supercoiled DNA and distamycin suggest major groove binding for the dppz and minor groove binding for the other complexes. Complexes 2-4 show efficient DNA cleavage activity on UV (365 nm) or red light (632.8 nm) irradiation via a mechanistic pathway involving formation of singlet oxygen as the reactive species. The DNA cleavage activity of the dpq complex 3 is found to be significantly more than its dppz and phen analogues

Metal-assisted red light-induced efficient DNA cleavage by dipyridoquinoxaline-copper(II) complex

Complete cleavage of double stranded pUC19 DNA by the complex [Cu(dpq)2(H2O)](ClO4)2 (dpq, dipyridoquinoxaline) has been observed on irradiation at 694 nm from a pulsed ruby laser, assisted by the metal d-band transition as well as the quinoxaline triplet states in the absence of any external additives

In vivo imaging with a cell-permeable porphyrin-based MRI contrast agent

Magnetic resonance imaging (MRI) with molecular probes offers the potential to monitor physiological parameters with comparatively high spatial and temporal resolution in living subjects. For detection of intracellular analytes, construction of cell-permeable imaging agents remains a challenge. Here we show that a porphyrin-based MRI molecular imaging agent, Mn-(DPA-C[subscript 2])[subscript 2]-TPPS[subscript 3], effectively penetrates cells and persistently stains living brain tissue in intracranially injected rats. Chromogenicity of the probe permitted direct visualization of its distribution by histology, in addition to MRI. Distribution was concentrated in cell bodies after hippocampal infusion. Mn-(DPA-C2)2-TPPS3 was designed to sense zinc ions, and contrast enhancement was more pronounced in the hippocampus, a zinc-rich brain region, than in the caudate nucleus, which contains relatively little labile Zn[superscript 2+]. Membrane permeability, optical activity, and high relaxivity of porphyrin-based contrast agents offer exceptional functionality for in vivo imaging.National Institutes of Health (U.S.) (grant DP2-OD2441)United States. Dept. of Defense (grant DAMD17-03-1-0413)National Institutes of Health (U.S.) (grant R01-GM065519

Engineering of Nanoparticles for Mitochondrial Trafficking of Therapeutics and Diagnosis of Cardiovascular Diseases

Shanta Dhar presented a lecture at the Nano@Tech Meeting on April 10, 2012 at 12 noon in room 1116 of the Marcus Nanotechnology Building.Dr. Dhar received her Ph.D. from the Indian Institute of Science, India. She was a postdoc in JHU where she developed sensors for detection of DNA lesions. In 2007, she joined MIT as an Anna Fuller fellow and worked on platinum-based cancer therapy. Currently, Dr. Dhar is an assistant professor in the chemistry department at the University of Georgia and an adjunct assistant professor in the Department of Physiology and Pharmacology. Her research program is in the field of nanomedicine. Dr. Dhar was recently awarded with Ralph E. Powe Junior Faculty Enhancement Award and Department of Defense Idea award.Runtime: 39:29 minutesThe potential benefits of integrating nanomaterials with properties such as biodegradability, magnetization, fluorescence, and near-infrared absorption into a single object of nanoscale dimensions can lead to the development of hybrid nano-medical platforms for simultaneous targeting, imaging, and combination therapy administration. We are developing hybrid nanoparticle (NP) systems such as hybrids of polymeric–gold nanoparticle and polymeric–iron oxide hybrid nanoparticle for their potential use in combination therapy of cancer and image-guided therapy of atherothrombotic vascular disease (ATVD), respectively. Mitochondrial dysfunctions cause many human disorders. A platform technology of carrying bioactive molecules to the mitochondrial matrix could be of enormous potential benefit in therapeutics. We are developing a rationally designed mitochondria-targeted NP system and its optimization for efficient delivery of a variety of mitochondria-acting therapeutics by blending a targeted poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol)-triphenylphosphonium (PLGA-b-PEG-TPP) polymer with either non-targeted PLGA-b-PEG-OH or PLGA-COOH. On the cardiovascular front, we are developing a long-circulating hybrid NP platform to selectively target macrophages and sense apoptosis for detection of plaque vulnerable to embolism. Apoptosis of cells along the arterial wall serves as a target for detection of plaque vulnerable to embolism. In this context, to detect atherosclerotic plaques noninvasively, we are developing MRI active NPs which can selectively target macrophages in the arteries and detect apoptotic cells with altered or compromised membranes. These highly engineered NPs include iron oxide in the core of a polymeric matrix for MRI detection, mannose for macrophage targeting, apoptotic cell targeting peptides, and a metal binding site for effective detection. The utility of these NPs in the diagnosis of atherosclerosis will be discussed

Abstract B56: Organelle targeted photodynamic therapy

Abstract The success of a cancer treatment is directly related to its ability to selectively kill cancer cells. Photodynamic therapy (PDT) with a photosensitizer (PS) that targets mitochondria causes a prompt release of cytochrome c into the cytoplasm and activation of caspases-9 and -3, among other caspases, that are responsible for initiating cell degradation. Photofrin is the FDA approved drug for PDT. Mitochondria have repeatedly been implicated as primary targets of porphyrin mediated PDT. However, a systematic study to direct the PDT drugs towards their cellular target, mitochondria of the cancer cell, is not yet fully explored. Phthalocyanins (Pc) are a class of compounds, which are known to successfully address the drawbacks exhibited by the porphyrin-based compounds. PDT, using the second-generation Pc, causes mitochondrial damage and induces apoptosis. However, the Pc molecules are hydrophobic and must be encapsulated within a liposomal formulation for successful delivery. Given that most effective PDT drug candidates act on the mitochondria of cancer cells and their hydrophobicity require suitable delivery vehicles for their intracellular accumulation, we hypothesize that the construction of engineered targeted drug delivery systems to direct PDT drugs to the mitochondria of the cancer cells would allow an effective phototherapeutic action. This would result in a higher local concentration of singlet oxygen in the mitochondria of cancer cells. In order to study this hypothesis, we have initiated the synthesis of a series of mitochondria targeting polymers to study nanoparticle (NP) assisted targeted delivery and anticancer properties of metallo phthalocyanins. The synthesis and biological activity of these constructs will be discussed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr B56.</jats:p

Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis

Atherosclerosis remains one of the most common causes of death in the United States and throughout the world because of the lack of early detection. Macrophage apoptosis is a major contributor to the instability of atherosclerotic lesions. Development of an apoptosis targeted high-density lipoprotein (HDL)-mimicking nanoparticle (NP) to carry contrast agents for early detection of vulnerable plaques and the initiation of preventative therapies that exploit the vascular protective effects of HDL can be attractive for atherosclerosis. Here, we report the construction of a synthetic, biodegradable HDL-NP platform for detection of vulnerable plaques by targeting the collapse of mitochondrial membrane potential that occurs during apoptosis. This HDL mimic contains a core of biodegradable poly(lactic-co-glycolic acid), cholesteryl oleate, and a phospholipid bilayer coat that is decorated with triphenylphosphonium (TPP) cations for detection of mitochondrial membrane potential collapse. The lipid layer provides the surface for adsorption of apolipoprotein (apo) A-I mimetic 4F peptide, and the core contains diagnostically active quantum dots (QDs) for optical imaging. In vitro uptake, detection of apoptosis, and cholesterol binding studies indicated promising detection ability and therapeutic potential of TPP-HDL-apoA-I-QD NPs. In vitro studies indicated the potential of these NPs in reverse cholesterol transport. In vivo biodistribution and pharmacokinetics indicated favorable tissue distribution, controlled pharmacokinetic parameters, and significant triglyceride reduction for i.v.-injected TPP-HDL-apoA-I-QD NPs in rats. These HDL NPs demonstrate excellent biocompatibility, stability, nontoxic, and nonimmunogenic properties, which prove to be promising for future translation in early plaque diagnosis and might find applications to prevent vulnerable plaque progression

Turn up the cellular power generator with vitamin E analogue formulation

The down regulation of the cellular power generator, adenosine triphosphate (ATP) synthase, in various cancer cells plays an obstructive role in mitochondria-mediated cell death. Cancer cells up-regulate ATPase inhibitory factor 1 (IF1) and down-regulate β-F -ATPase of ATP synthase to enhance aerobic glycolysis for tumor growth inhibiting total ATP synthase activity in the oxidative phosphorylation (OXPHOS) pathway. Alpha-tocopheryl succinate (α-TOS), one of the most bioactive derivatives of vitamin E, can selectively induce apoptosis in numerous cancer cells. The cancer cell selective apoptosis inducing property of α-TOS is correlated to: mitochondrial destabilization, inhibition of anti-apoptotic B cell lymphoma 2 (Bcl2) and protein kinase C (PKC), caspase 3 activation, production of mitochondrial reactive oxygen species (ROS), and inhibition of succinate dehydrogenase activity of mitochondrial complex II, and interaction with complex I to some extent. There is no report which elucidates the effects of α-TOS on the cellular power generator, complex V or ATP synthase. Here, we report the activation of mitochondrial ATP synthase using a suitably designed chemical formulation of α-TOS for the first time. A mitochondria targeted α-TOS nanoparticle formulation demonstrated enhanced cytotoxicity and mitochondrial activities in cancer cells by inhibiting Bcl2 protein and activating ATP synthase. The modulation of ATP synthase in cancer cells by the engineered formulation of α-TOS can be promising for solid cancers with compromised ATP synthase

Centrifugation‐Free Magnetic Isolation of Functional Mitochondria Using Paramagnetic Iron Oxide Nanoparticles

Subcellular fractionation techniques are essential for cell biology and drug development studies. The emergence of organelle-targeted nanoparticle (NP) platforms necessitates the isolation of target organelles to study drug delivery and activity. Mitochondria-targeted NPs have attracted the attention of researchers around the globe, since mitochondrial dysfunctions can cause a wide range of diseases. Conventional mitochondria isolation methods involve high-speed centrifugation. The problem with high-speed centrifugation-based isolation of NP-loaded mitochondria is that NPs can pellet even if they are not bound to mitochondria. We report development of a mitochondria-targeted paramagnetic iron oxide nanoparticle, Mito-magneto, that enables isolation of mitochondria under the influence of a magnetic field. Isolation of mitochondria using Mito-magneto eliminates artifacts typically associated with centrifugation-based isolation of NP-loaded mitochondria, thus producing intact, pure, and respiration-active mitochondria. © 2017 by John Wiley & Sons, Inc

Controlled release nanoplatforms for three commonly used chemotherapeutics

In order to combat an evolving, multidimensional disease such as cancer, research has been aimed at synthesizing more efficient and effective versions of popular chemotherapeutic drugs. Despite these efforts, there remains a necessity for the development of suitable delivery vehicles that can both harness the chemotherapeutic effects meanwhile reducing some of the known issues when using these drugs such as unwanted side-effects, acquired drug resistance, and associated difficulties with drug delivery. Synthetic drug discovery approaches focusing on modification of the native structure of these chemotherapeutic drugs often face challenges such as loss of efficacy, as well as a potential worsening of side-effects. Synthetic chemists are then left with increasingly narrow choices for possible chemistry they could implement to achieve the desired therapy. The emergence of targeted therapies using controlled-release nanomaterials can provide many opportunities for conventional chemotherapeutic drugs to be delivered to specific target sites, ultimately leading to reduced side-effects and improved efficacy. Logically, it may prove advantageous to consider nano-delivery systems as a likely candidate for circumventing some of the barriers associated with creating viable drug therapies. In this review, we summarize controlled release nanoformulations of the three most widely used and approved chemotherapeutics, doxorubicin, paclitaxel, and cisplatin as an alternative therapeutic approach against different cancer types